Literature DB >> 33467010

Modulating Protein-Protein Interactions by Cyclic and Macrocyclic Peptides. Prominent Strategies and Examples.

Rosario González-Muñiz1, María Ángeles Bonache1, María Jesús Pérez de Vega1.   

Abstract

Cyclic and macrocyclic peptides constitute advanced molecules for modulating protein-protein interactions (PPIs). Although still peptide derivatives, they are metabolically more stable than linear counterparts, and should have a lower degree of flexibility, with more defined secondary structure conformations that can be adapted to imitate protein interfaces. In this review, we analyze recent progress on the main methods to access cyclic/macrocyclic peptide derivatives, with emphasis in a few selected examples designed to interfere within PPIs. These types of peptides can be from natural origin, or prepared by biochemical or synthetic methodologies, and their design could be aided by computational approaches. Some advances to facilitate the permeability of these quite big molecules by conjugation with cell penetrating peptides, and the incorporation of β-amino acid and peptoid structures to improve metabolic stability, are also commented. It is predicted that this field of research could have an important future mission, running in parallel to the discovery of new, relevant PPIs involved in pathological processes.

Entities:  

Keywords:  biochemical methodologies; cell penetrating conjugates; computational design; cyclic peptides; macrocyclic peptides; peptoids; protein–protein interactions; synthetic strategies

Mesh:

Substances:

Year:  2021        PMID: 33467010      PMCID: PMC7830901          DOI: 10.3390/molecules26020445

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


  100 in total

Review 1.  Protein-protein interactions as drug targets.

Authors:  Malgorzata Skwarczynska; Christian Ottmann
Journal:  Future Med Chem       Date:  2015-10-29       Impact factor: 3.808

2.  beta-Peptides as inhibitors of protein-protein interactions.

Authors:  Joshua A Kritzer; Olen M Stephens; Danielle A Guarracino; Samuel K Reznik; Alanna Schepartz
Journal:  Bioorg Med Chem       Date:  2005-01-03       Impact factor: 3.641

Review 3.  A Review of Stapled Peptides and Small Molecules to Inhibit Protein-Protein Interactions in Cancer.

Authors:  Vidhya V Iyer
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

Review 4.  Hydrocarbon stapled peptides as modulators of biological function.

Authors:  Philipp M Cromm; Jochen Spiegel; Tom N Grossmann
Journal:  ACS Chem Biol       Date:  2015-03-31       Impact factor: 5.100

5.  High-Affinity α5β1-Integrin-Selective Bicyclic RGD Peptides Identified via Screening of Designed Random Libraries.

Authors:  Dominik Bernhagen; Vanessa Jungbluth; Nestor Gisbert Quilis; Jakub Dostalek; Paul B White; Kees Jalink; Peter Timmerman
Journal:  ACS Comb Sci       Date:  2019-08-01       Impact factor: 3.784

6.  Computational method to identify druggable binding sites that target protein-protein interactions.

Authors:  Hubert Li; Vinod Kasam; Christofer S Tautermann; Daniel Seeliger; Nagarajan Vaidehi
Journal:  J Chem Inf Model       Date:  2014-05-07       Impact factor: 4.956

Review 7.  Therapeutic design of peptide modulators of protein-protein interactions in membranes.

Authors:  Tracy A Stone; Charles M Deber
Journal:  Biochim Biophys Acta Biomembr       Date:  2016-08-28       Impact factor: 3.747

8.  A peptoid "antibody surrogate" that antagonizes VEGF receptor 2 activity.

Authors:  D Gomika Udugamasooriya; Sean P Dineen; Rolf A Brekken; Thomas Kodadek
Journal:  J Am Chem Soc       Date:  2008-04-02       Impact factor: 15.419

9.  Screening bicyclic peptide libraries for protein-protein interaction inhibitors: discovery of a tumor necrosis factor-α antagonist.

Authors:  Wenlong Lian; Punit Upadhyaya; Curran A Rhodes; Yusen Liu; Dehua Pei
Journal:  J Am Chem Soc       Date:  2013-08-01       Impact factor: 15.419

10.  Dinitroimidazoles as bifunctional bioconjugation reagents for protein functionalization and peptide macrocyclization.

Authors:  Qunfeng Luo; Youqi Tao; Wangjian Sheng; Jingxia Lu; Huan Wang
Journal:  Nat Commun       Date:  2019-01-11       Impact factor: 14.919

View more
  6 in total

Review 1.  Targeting intracellular protein-protein interactions with macrocyclic peptides.

Authors:  Marina Buyanova; Dehua Pei
Journal:  Trends Pharmacol Sci       Date:  2021-12-13       Impact factor: 14.819

2.  Optimization of eIF4E-Binding Peptide Pep8 to Disrupt the RBM38-eIF4E Complex for Induction of p53 and Tumor Suppression.

Authors:  Christopher A Lucchesi; Jin Zhang; Demitria M Vasilatis; Elizabeth Yip; Xinbin Chen
Journal:  Front Oncol       Date:  2022-04-28       Impact factor: 5.738

3.  Structure-Based Cyclic Glycoprotein Ibα-Derived Peptides Interfering with von Willebrand Factor-Binding, Affecting Platelet Aggregation under Shear.

Authors:  Johana Hrdinova; Delia I Fernández; Bogac Ercig; Bibian M E Tullemans; Dennis P L Suylen; Stijn M Agten; Kerstin Jurk; Tilman M Hackeng; Karen Vanhoorelbeke; Jan Voorberg; Chris P M Reutelingsperger; Kanin Wichapong; Johan W M Heemskerk; Gerry A F Nicolaes
Journal:  Int J Mol Sci       Date:  2022-02-12       Impact factor: 5.923

4.  A Modular Synthesis of Teraryl-Based α-Helix Mimetics, Part 3: Iodophenyltriflate Core Fragments Featuring Side Chains of Proteinogenic Amino Acids.

Authors:  Melanie Trobe; Martin Vareka; Till Schreiner; Patrick Dobrounig; Carina Doler; Ella B Holzinger; Andreas Steinegger; Rolf Breinbauer
Journal:  European J Org Chem       Date:  2022-02-24

5.  Peptide Based Inhibitors of Protein Binding to the Mitogen-Activated Protein Kinase Docking Groove.

Authors:  Anita Alexa; Orsolya Ember; Ildikó Szabó; Yousef Mo'ath; Ádám L Póti; Attila Reményi; Zoltán Bánóczi
Journal:  Front Mol Biosci       Date:  2021-07-01

Review 6.  Interfacial Peptides as Affinity Modulating Agents of Protein-Protein Interactions.

Authors:  Pavel V Ershov; Yuri V Mezentsev; Alexis S Ivanov
Journal:  Biomolecules       Date:  2022-01-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.